Vinorelbine’s anti-tumor actions may depend on the mitotic apoptosis, autophagy and inflammation: hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas

References

• Hanley ML, Elion GB, Colvin OM, et al. Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemother Pharmacol. 1998;42:479–482.
   PubMed Web of Science ®Google Scholar
• Sato H, Fukumoto K, Hada S, et al. Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells. Cancer Chemother Pharmacol. 2007;60:449–457.
   PubMed Web of Science ®Google Scholar
• Okouneva T, Hill BT, Wilson L, et al. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther. 2003;2:427–436.
   PubMed Web of Science ®Google Scholar
• Fukuoka K, Arioka H, Iwamoto Y, et al. Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer. 2001;34:451–460.
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Inoue T. Antiproliferative fate of the tetraploid formed after mitotic slippage and its promotion; a novel target for cancer therapy based on microtubule poisons. Molecules. 2016;21:pii: E663. doi:10.3390/molecules21050663
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhou Y, Shi J. Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle. Cell Cycle. 2014;13:1756–1764.
   PubMed Web of Science ®Google Scholar
• Tsuiki H, Nitta M, Tada M, et al. Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines. Oncogene. 2001;20:420–429.
   PubMed Web of Science ®Google Scholar
• Castigli E, Sciaccaluga M, Schiavoni G, et al. GL15 and U251 glioblastoma-derived human cell lines are peculiarly susceptible to induction of mitotic death by very low concentrations of okadaic acid. Oncol Rep. 2006;15:463–470.
   PubMed Web of Science ®Google Scholar
• Réz G, Csák J, Fellinger E, et al. Time course of vinblastine-induced autophagocytosis and changes in the endoplasmic reticulum in murine pancreatic acinar cells: a morphometric and biochemical study. Eur J Cell Biol. 1996;71:341–350.
   PubMed Web of Science ®Google Scholar
• Köchl R, Hu XW, Chan EY, et al. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic. 2006;7:129–145.
   PubMed Web of Science ®Google Scholar
• Fu X, Pan Y, Wang et al. The role of autophagy in human lung cancer cell line A549 induced by Vinorelbine. Zhongguo Fei Ai Za Zhi. 2008;11:345–348.
   PubMedGoogle Scholar
• Greer RM, Peyton M, Larsen JE, et al. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner. Cancer Res. 2011;71:7640–7648.
   PubMed Web of Science ®Google Scholar
• Miyahara K, Kazama H, Kokuba H, et al. Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines. Int J Oncol. 2016;49:1848–1858.
   PubMed Web of Science ®Google Scholar
• Vincent LA, Attaoua C, Bellis M, et al. Lysosomes and unfolded protein response, determinants of differential resistance of melanoma cells to vinca alkaloids. Fundam Clin Pharmacol. 2015;29:164–177.
   PubMed Web of Science ®Google Scholar
• Gebbia V, Testa A, Valenza R, et al. Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity. Eur J Cancer. 1994;30A:889.
   PubMed Web of Science ®Google Scholar
• De Marco S, Fabi A, Ceribelli A, et al. Does pain at tumor site during vinorelbine infusion affect treatment of recurrent head and neck cancer patients? Ann Oncol. 1999;10:865–866.
   PubMed Web of Science ®Google Scholar
• Kornek GV, Kornfehl H, Hejna M, et al. Acute tumor pain in patients with head and neck cancer treated with vinorelbine. J Natl Cancer Inst. 1996;88:1593.
   PubMedGoogle Scholar
• Porzio G, Aielli F, Verna L, et al. Morphine in the treatment of incident pain triggered by vinorelbine infusion. J Pain Symptom Manage. 2008;35:238–239.
   PubMed Web of Science ®Google Scholar
• Zhu ZF, Fan M, Fu XL. Radiation recall with vinorelbine and cisplatin. Onkologie. 2010;33:107–109.
   PubMedGoogle Scholar
• Vivaldi A, Ciampi R, Tacito A, et al. Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. Mol Cell Endocrinol. 2012;355:41–48.
   PubMed Web of Science ®Google Scholar
• Duffy CP, Elliott CJ, O'Connor RA, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer. 1998;34:1250–1259.
   PubMed Web of Science ®Google Scholar
• Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci U S A. 1998;95:3896–3901.
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000;275:14838–14845.
   PubMed Web of Science ®Google Scholar
• Munkarah AR, Genhai Z, Morris R, et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol. 2003;88:429–433.
   Google Scholar
• Eichele K, Ramer R, Hinz B. Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene. 2008;27:3032–3044.
   PubMed Web of Science ®Google Scholar
• Cassidy PB, Moos PJ, Kelly RC, et al. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin Cancer Res. 2002;8:846–855.
   PubMed Web of Science ®Google Scholar
• Biziota E, Briasoulis E, Mavroeidis L, et al. Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells. Anticancer Drugs. 2016;27:216–224.
   PubMed Web of Science ®Google Scholar
• Fang D, Sun L, Lin S, et al. Vinorelbine inhibits angiogenesis and 95D migration via reducing hypoxic fibroblast stromal cell-derived factor 1 secretion. Exp Biol Med (Maywood). 2012;237:1045–1055.
   PubMed Web of Science ®Google Scholar
• Qian W, Gao L, Chen C, et al. Involvement of Toll-like receptor 4 in vinorelbine-induced vascular endothelial injury. Exp Ther Med. 2015;10:62–66.
   PubMed Web of Science ®Google Scholar
• Tsai KL, Huang PH, Kao CL, et al. Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis. Biochem Pharmacol. 2014;88:189–200.
   PubMed Web of Science ®Google Scholar
• Tralongo P, Di Mari A, Agueli R, et al. Oral vinorelbine may not induce acute pain at the tumor site. J Pain Symptom Manage. 2006;32:197–199.
   PubMed Web of Science ®Google Scholar
• Soliman E, Henderson KL, Danell AS, et al. Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: role of cyclooxygenase-2 and novel J-series prostamides. Mol Carcinog. 2016;55:117–130.
   PubMed Web of Science ®Google Scholar
• Na HK, Surh YJ. Induction of cyclooxygenase-2 in Ras-transformed human mammary epithelial cells undergoing apoptosis. Ann N Y Acad Sci. 2002;973:153–160.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Bianchi A, Curreli L, et al. Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study. Biotherapy. 1994;8:91–98.
   PubMedGoogle Scholar
• Schmidinger M, Steger GG, Budinsky AC, et al. Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma. Anticancer Drugs. 2000;11:175–179.
   PubMed Web of Science ®Google Scholar
• Mencoboni MP, Tredici S, Varaldo M, et al. Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma. Neoplasma. 2006;53:333–336.
   PubMed Web of Science ®Google Scholar
• Gogas H, Bafaloukos D, Aravantinos G, et al. Hellenic Cooperative Oncology Group. Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Cancer Invest. 2004;22:832–839.
   PubMed Web of Science ®Google Scholar
• Vuoristo MS, Vihinen P, Skyttä T, et al. Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis. Anticancer Res. 2009;29:1755–1759.
   PubMed Web of Science ®Google Scholar
• Zhong R, Teng J, Han B, et al. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011;60:1497–1502.
   PubMed Web of Science ®Google Scholar
• Ogura K, Ohta S, Ohmori T, et al. Vinca alkaloids induce granulocyte-macrophage colony stimulating factor in human peripheral blood mononuclear cells. Anticancer Res. 2000;20:2383–2388.
   PubMed Web of Science ®Google Scholar
• Asakura H, Takashima H, Mitani M, et al. Unknown primary carcinoma, diagnosed as inflammatory breast cancer, and successfully treated with trastuzumab and vinorelbine. Int J Clin Oncol. 2005;10:285–288.
   PubMedGoogle Scholar
• Clemente M, Sánchez-Archidona AR, Sardón D, et al. Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer. Vet J. 2013;197:427–432.
   PubMed Web of Science ®Google Scholar
• Raposo TP, Pires I, Prada J, et al. Exploring new biomarkers in the tumour microenvironment of canine inflammatory mammary tumours. Vet Comp Oncol. 2017;15(2):655–666. doi:10.1111/vco.12209
   Web of Science ®Google Scholar
• Ardavanis A, Scorilas A, Tryfonopoulos D, et al. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist. 2006;11:563–573.
   PubMed Web of Science ®Google Scholar
• Costa SD, Loibl S, Kaufmann M, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol. 2010;28:83–91.
   PubMed Web of Science ®Google Scholar
• Abrous-Anane S, Savignoni A, Daveau C, et al. Management of inflammatory breast cancer after neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2011;79:1055–1063.
   PubMed Web of Science ®Google Scholar
• Biassoni V, Casanova M, Spreafico F, et al. A case of relapsing glioblastoma multiforme responding to vinorelbine. J Neurooncol. 2006;80:195–201.
   PubMed Web of Science ®Google Scholar
• Massimino M, Spreafico F, Biassoni V, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol. 2008;87:355–361.
   PubMed Web of Science ®Google Scholar
• Kuttesch JF Jr, Krailo MD, Madden T, et al. Children’s Oncology Group. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. Pediatr Blood Cancer. 2009;53:590–593.
   PubMed Web of Science ®Google Scholar
• Cappellano AM, Bouffet E, Cavalheiro S, et al. Diffuse intrinsic brainstem tumor in an infant: a case of therapeutic efficacy with vinorelbine. J Pediatr Hematol Oncol. 2011;33:116–118.
   PubMed Web of Science ®Google Scholar
• Massimino M, Biassoni V, Miceli R, et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118:305–312.
   PubMed Web of Science ®Google Scholar
• Cappellano AM, Petrilli AS, da Silva NS, et al. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol. 2015;121:405–412.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Kamezaki T, Shibata Y, et al. Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors. Neurol Med Chir (Tokyo). 1995;35:22–27.
   PubMedGoogle Scholar
• Warren K, Bent R, Wolters PL, et al. A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma. Cancer. 2012;118:3607–3613.
   PubMed Web of Science ®Google Scholar
• Tuna S, Altinoz MA, Karasu A, et al. Selective COX-2 inhibitor (rofecoxib) inhibits vinorelbine cytotoxicity in C6 glioma cells in vitro Open Pathol J. 2009;3:22–29.
   Google Scholar
• Vacchelli E, Eggermont A, Sautès-Fridman C, et al. Trial watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2013;2:e25238.
   PubMed Web of Science ®Google Scholar
• Hardin C, Shum E, Singh AP, et al. Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. Expert Opin Pharmacother. 2017;18:701–716. doi:10.1080/14656566.2017.1316374
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Waypa J, Blaydorn L, et al. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017;117:33–40. doi:10.1038/bjc.2017.145
   PubMed Web of Science ®Google Scholar
• Terra SBSP, Mansfield AS, Dong H, et al. Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. Oncoimmunology. 2017;6:e1356146. doi:10.1080/2162402X.2017.1356146
   PubMed Web of Science ®Google Scholar
• Liu XM, Wang LG, Kreis W, et al. Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. Br J Cancer. 2001;85:1403–1411.
   PubMed Web of Science ®Google Scholar
• Li H, Sun L, Li H, et al. DT-13, a saponin monomer 13 of the Dwarf lilyturf tuber, synergized with vinorelbine to induce mitotic arrest via activation of ERK signaling pathway in NCI-H1299 cells. Biomed Pharmacother. 2017;89:1277–1285. doi:10.1016/j.biopha.2017.02.104
   PubMed Web of Science ®Google Scholar
• Fan DP, Zhang YM, Hu XC, et al. Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine. Int J Clin Exp Pathol. 2013;7:134–143.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tanimura S, Uchiyama A, et al. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. Clin Cancer Res. 2010;16:1170–1178. doi:10.1158/1078-0432.CCR-09-2482
   PubMed Web of Science ®Google Scholar
• Shi Y, Chen L, Li J, et al. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol. 2011;32:381–390. doi:10.1007/s13277-010-0131-8
   PubMed Web of Science ®Google Scholar